title: Clinical outcomes of everolimus- and zotarolimus-eluting stents in patients with acute myocardial infarction for small coronary artery disease.
abstract: OBJECTIVE
  There were limited data about comparison of zotarolimus-eluting stents (ZES) and everolimus-eluting stents (EES) in patients with small coronary artery disease (CAD), especially in patients with acute myocardial infarction (AMI). The objective of this study was to compare the clinical outcomes of ZES and EES in patients with AMI for small CAD.
  
  
  METHODS
  A total 1565 AMI patients treated with Endeavor-ZES (n=651) (Medtronic CardioVascular, Santa Rosa, CA, USA) or Xience V/Promus-EES (n=914) (Abbott Vascular, Temecula, CA/Boston Scientific, Natick, MA, USA) for small CAD (stent diameter ≤ 2.75 mm) in KAMIR (Korea Acute Myocardial Infarction Registry) were enrolled. After propensity score matching to adjust for baseline clinical and angiographic characteristics, we compared a total 1302 patients (651 ZES and 651 EES) about major adverse cardiac events (MACE) at 1-year. Subgroup analysis about 1-year clinical outcomes was undertaken in patients who were discharged alive.
  
  
  RESULTS
  Baseline clinical and angiographic characteristics were similar between the two groups after propensity score matching. Total MACE did not differ between the two groups before (9.8% vs. 8.2%, p=0.265) and after (9.8% vs. 9.4%, p=0.778) propensity score matching. The EES group showed lower rate of 1-year cardiac death (5.4% vs. 3.3%, p=0.041), target lesion failure (TLF; 6.9% vs. 4.3%, p=0.022), and stent thrombosis (1.4% vs. 0.4%, p=0.042) compared with the ZES group. However, there were no differences in 1-year cardiac death, TLF, and stent thrombosis in propensity score matched populations. Other various 1-year clinical outcomes showed no difference between the two groups. Subgroup analysis in patients who were discharged alive showed similar outcomes between the two groups at 1-year follow-up.
  
  
  CONCLUSIONS
  In-this propensity score matched analysis, EES and ZES showed no significant difference in clinical outcomes at 1-year follow-up in patients with AMI for small CAD.
authors: Department of Cardiology, Gwangju Veterans Hospital, Gwangju, Republic of Korea.
authors: Sang Cheol
authors: SC
authors: Cho
authors: Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea. Electronic address: myungho@chollian.net.
authors: Myung Ho
authors: MH
authors: Jeong
authors: Department of Cardiology, Gwangju Veterans Hospital, Gwangju, Republic of Korea.
authors: Wan
authors: W
authors: Kim
authors: Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea.
authors: Youngkeun
authors: Y
authors: Ahn
authors: Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea.
authors: Young Joon
authors: YJ
authors: Hong
authors: Yeungnam University Hospital, Daegu, Republic of Korea.
authors: Young Jo
authors: YJ
authors: Kim
authors: Kyung Hee University Hospital, Seoul, Republic of Korea.
authors: Chong Jin
authors: CJ
authors: Kim
authors: Chungbuk National University Hospital, Cheongju, Republic of Korea.
authors: Myeong Chan
authors: MC
authors: Cho
authors: Hallym University College of Medicine, Seoul, Republic of Korea.
authors: Kyoo Rok
authors: KR
authors: Han
authors: Seoul National University Hospital, Seoul, Republic of Korea.
authors: Hyo Soo
authors: HS
authors: Kim
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D003331:Coronary Vessels / Q000473:pathology; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D057216:Propensity Score; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000068338:Everolimus; C489443:zotarolimus; D020123:Sirolimus
keywords: Everolimus-eluting stent; Small coronary artery disease; Zotarolimus-eluting stent